We found that replacement of the CMV enhancer promoter with the TETP allowed tight melanoma-specific transgene expression, as IL-2 expression levels amounted to a minimal 149-fold to a maximal 5652-fold higher expression levels in melanoma cells compared to HeLa cells. The gene discussed is IL2; the disease is melanoma.